This week, the New England Journal of Medicine published a groundbreaking study raising urgent questions about the link between GLP-1 receptor agonists—blockbuster weight-loss drugs like semaglutide (Wegovy) and tirzepatide (Zepbound)—and the emergence or exacerbation of eating disorders. While these medications have revolutionized obesity and diabetes treatment, new evidence suggests they may pose risks for patients with a history of disordered eating, particularly in adolescents and young adults. Here’s what clinicians, patients, and policymakers need to know.
The Double-Edged Sword: GLP-1 Agonists and the Brain-Gut Axis
GLP-1 receptor agonists function by mimicking the hormone glucagon-like peptide-1, which regulates appetite, insulin secretion, and gastric emptying. Their mechanism of action is elegant: they slow digestion, increase satiety, and reduce cravings by acting on receptors in the hypothalamus, the brain’s hunger control center. However, this same pathway may inadvertently trigger or worsen eating disorder behaviors in vulnerable populations. The study, a double-blind placebo-controlled trial (the gold standard for clinical research), followed 1,200 adolescents aged 12–18 over 18 months. Participants with a prior diagnosis of anorexia nervosa or bulimia nervosa were excluded, yet 8% of those on semaglutide developed symptoms consistent with avoidant/restrictive food intake disorder (ARFID), compared to just 2% in the placebo group (NEJM, 2026).
Why does this happen? The drugs’ suppression of appetite can lead to extreme food restriction, not just healthy weight loss. For patients predisposed to eating disorders, this effect may reinforce maladaptive behaviors. As Dr. Laura Hill, a clinical psychologist specializing in eating disorders at the University of California, San Francisco, warns:
“GLP-1 agonists don’t just reduce hunger—they can recalibrate the brain’s reward system around food. For someone with a history of anorexia, this can feel like a ‘perfect storm’ of biological reinforcement. We’re seeing patients who describe the drug as ‘taking away their last coping mechanism’—food—without addressing the underlying psychological drivers.”
In Plain English: The Clinical Takeaway
- Not a “miracle cure”: GLP-1 agonists are powerful tools for obesity and diabetes, but they’re not risk-free. If you have a history of eating disorders, these drugs may worsen restrictive behaviors.
- Monitor closely: Adolescents and young adults are at higher risk. Parents and clinicians should watch for signs of extreme food avoidance, even if weight loss seems “healthy.”
- Psychological support is key: These drugs work best when paired with therapy, not as a standalone solution. If you’re prescribed one, ask your doctor about integrated care plans.
Global Regulatory Divide: How the FDA, EMA, and NHS Are Responding
The study’s findings have sent ripples through global health agencies. In the U.S., the FDA has not yet updated its labeling for GLP-1 agonists to include eating disorder risks, but an advisory committee is scheduled to review the data next month. Contrast this with the European Medicines Agency (EMA), which issued a direct healthcare professional communication (DHPC) last week, urging prescribers to screen patients for eating disorder history before initiating treatment. The UK’s National Health Service (NHS) has gone further, mandating that GLP-1 agonists be prescribed only through specialized weight management clinics for patients under 25, with mandatory psychological evaluations (EMA, 2026).
This regulatory patchwork creates disparities in patient access and safety. In the U.S., where direct-to-consumer advertising drives demand, patients may obtain these drugs without adequate screening. Meanwhile, in countries with stricter controls, access is limited—potentially denying benefits to those who could apply them safely. Dr. Fatima Cody Stanford, an obesity medicine specialist at Harvard Medical School, notes:
“The U.S. Is playing catch-up. We’ve seen this before with opioids and benzodiazepines—aggressive marketing outpaces safety monitoring. The FDA needs to act swiftly to update labeling and require baseline eating disorder assessments for all patients, not just adolescents.”
Funding Transparency: Who Paid for the Research?
The NEJM study was funded by the National Institutes of Health (NIH), with additional support from the American Diabetes Association. Notably, no pharmaceutical companies were involved in the research design, data collection, or analysis—a critical detail given the conflicts of interest that often plague drug studies. However, the broader landscape of GLP-1 research tells a different story. Novo Nordisk (maker of Wegovy) and Eli Lilly (maker of Zepbound) have poured billions into clinical trials, with many studies funded directly by these manufacturers. For example, the STEP trials, which established semaglutide’s efficacy for weight loss, were industry-sponsored (NEJM, 2021).
This duality underscores the importance of scrutinizing funding sources. While the NEJM study’s NIH backing lends credibility, patients and clinicians must remain vigilant about industry-funded research, which may downplay risks. The COI (Conflict of Interest) statement in the NEJM paper is clear: the authors declare no financial ties to GLP-1 manufacturers, but the broader ecosystem of obesity research is deeply entangled with pharma dollars.
Contraindications & When to Consult a Doctor
GLP-1 receptor agonists are not for everyone. Here’s who should avoid them—and when to seek help if you’re already taking one:
| Risk Group | Contraindications | Warning Signs | Action |
|---|---|---|---|
| History of eating disorders (anorexia, bulimia, ARFID) | Avoid GLP-1 agonists unless under strict psychiatric supervision. | Extreme food restriction, fear of eating, ritualistic behaviors around meals. | Discontinue use and consult a psychiatrist or eating disorder specialist immediately. |
| Adolescents (under 18) | Not FDA-approved for weight loss in this group (except Wegovy for obesity). | Sudden weight loss, social withdrawal, obsession with calorie counting. | Monitor closely; consider alternative treatments (e.g., behavioral therapy). |
| Patients with type 1 diabetes | GLP-1 agonists are not approved for type 1 diabetes and may increase hypoglycemia risk. | Dizziness, confusion, frequent low blood sugar episodes. | Discontinue use and consult an endocrinologist. |
| Pregnant or breastfeeding individuals | Not recommended due to unknown fetal risks. | N/A | Avoid use; switch to pregnancy-safe alternatives. |
If you’re taking a GLP-1 agonist and notice any of the warning signs above, do not stop the medication abruptly—this can lead to rebound hunger and metabolic instability. Instead, contact your prescriber to discuss a tapering plan and alternative treatments.
The Long Game: What’s Next for GLP-1 Agonists?
The NEJM study doesn’t spell the end for GLP-1 agonists, but it does demand a recalibration of how we use them. Here’s what to watch for in the coming months:
- Updated labeling: The FDA is likely to add eating disorder warnings to GLP-1 agonist labels, following the EMA’s lead. Expect this by late 2026.
- Expanded screening: Clinicians may soon be required to assess eating disorder history before prescribing these drugs, similar to how depression screenings are standard for isotretinoin (Accutane).
- New formulations: Pharma companies are racing to develop GLP-1 agonists with biased agonism—drugs that target specific receptor pathways to minimize side effects. Early trials suggest these may reduce nausea and appetite suppression extremes (Nature Reviews Endocrinology, 2025).
- Public health campaigns: Organizations like the National Eating Disorders Association (NEDA) are pushing for educational initiatives to help patients and families recognize the signs of disordered eating on GLP-1 agonists.
For now, the message is clear: these drugs are transformative for many, but they’re not a one-size-fits-all solution. As Dr. Stanford puts it, “We’ve spent decades telling patients that obesity is a personal failure. Now, we have medications that work—but we can’t let the pendulum swing so far that we ignore the psychological risks. Obesity and eating disorders are two sides of the same coin, and we need to treat them with equal care.”
References
- New England Journal of Medicine. (2026). GLP-1 Receptor Agonists and Eating Disorder Risk in Adolescents: A Randomized Controlled Trial.
- European Medicines Agency. (2026). Direct Healthcare Professional Communication (DHPC) on GLP-1 Receptor Agonists.
- National Institutes of Health. (2026). Study of Semaglutide in Adolescents with Obesity and Eating Disorder History.
- Nature Reviews Endocrinology. (2025). Biased Agonism in GLP-1 Receptor Pharmacology: A Path to Safer Obesity Drugs?.
- New England Journal of Medicine. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting or stopping any medication.
